3SBio Announces Solid Q2; Looks Toward Biosimilar Market

3SBio Inc. (沈阳三生制药)reported that Q2 revenues increased a steady 37% over the year-earlier quarter. As further good news, the company said net income kept pace with the rise in sales, climbing 39% on a GAAP basis. To increase revenues in the future, 3SBio is constructing a new manufacturing facility, which will increase production capacity of its recombinant human erythropoietin (EPO) four-fold. The company is positioning itself to supply biosimilar products to countries that allow biosimilar drugs into their markets. More details... Stock Symbol: (NSDQ: SSRX)